Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center

Despite the dramatic improvements in recurrence-free survival in patients with metastatic melanoma treated with immune checkpoint inhibitors (ICI), a number of patients develop metastases during adjuvant therapy. It is not currently possible to predict which patients are most likely to develop disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurzhals, Jonas K., Klee, Gina, Hagelstein, Victoria, Zillikens, Detlef, Terheyden, Patrick, Langan, Ewan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505359/
https://www.ncbi.nlm.nih.gov/pubmed/36142629
http://dx.doi.org/10.3390/ijms231810723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505359/
https://www.ncbi.nlm.nih.gov/pubmed/36142629
http://dx.doi.org/10.3390/ijms231810723

Ejemplares similares